Isolation of PD-1 ligands and their application for immunosuppression
Isolation of PD-1 ligands and their application for immunosuppression
批准号:
12557030
负责人:
HONJO Tasuku
金额:
$8.64万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2000
资助国家:
日本
项目状态:
已结题
起止时间:
2000 至 2001
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PD-1 -deficient mice develop a variety of autoimmune-like diseases, which suggests that this immunoinhibitory receptor plays an important role in tolerance. We identified PD-1 ligand 1 and 2 (PD-L1 and PD-L2) as ligands for PD-1 by computer-based homology search. Both ligands are expressed on nonlymphoid tissues, such as heart or liver. Engagement of PD-1 by PD-1 ligands leads to the inhibition of T cell receptor mediated lymphocyte proliferation and cytokine secretion. In addition, PD-1 signaling can inhibit at least suboptimal levels of CD28-mediated costimulation. PD-ligands are expressed by antigen-presenting cells, including human peripheral blood monocytes stimulated with interferon, and activated human and murine dendritic cells. Therefore, the relative levels of inhibitory PD-1 ligands and costimulatory B7-1/B7-2 signals on antigen presenting cells may determine the extent of lymphocyte activation and consequently the threshold between tolerance and autoimmunity.In addition, we … More also generated chimeric molecules composed of the IgG Fc receptor type IIB extracellular region and the PD-1 cytoplasmic region and expressed them in a B lymphoma cell line, IIA1.6. Coligation of the cytoplasmic region of PD-1 with the B cell receptor (BCR) in IIA1.6 transformants inhibited BCR-mediated growth retardation, and tyrosine phosphorylation of effector molecules, including Ig beta, Syk, phospholipase C-gamma 2 and ERK1/2. Mutagenesis studies indicated that these inhibitory effects do not require the N-terminal tyrosine in the immunoreceptor tyrosine-based inhibitory motif-like sequence, but do require the other tyrosine residue in the C-terminal tail. This tyrosine was phosphorylated and recruited src homology 2-domain-containing tyrosine phosphatase 2 (SHP-2) on cologation of PD-1 with BCR. These results show that PD-1 can inhibit BCR signaling by recruiting SHP-2 to its phosphotyrosine and dephosphorylating key signal transducers of BCR signaling.Taken together, we identified two PD-1 ligands and showed that the inhibitory signal of PD-1 is mediated by SHP-2. Less
期刊论文(30)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Carter, L. et al.: "PD-1: PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2"Eur. J. Immunol.. 32. 634-643 (2002)
Carter, L. 等人:“PD-1:PD-L 抑制途径影响 CD4( ) 和 CD8( ) T 细胞,并被 IL-2 克服”Eur。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Okazaki, T., Maeda, A., Nishimura, H., Honjo, T.: "PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting Src homology2-domain-containing tyrosine phospatase 2 to phosphotyrosine"Proc.Natl.Acad.Sci.USA. 98. 13866-13871 (2001)
Okazaki, T.、Maeda, A.、Nishimura, H.、Honjo, T.:“PD-1 免疫受体通过将包含 Src 同源 2 结构域的酪氨酸磷酸酶 2 募集到磷酸酪氨酸来抑制 B 细胞受体介导的信号传导”Proc.Natl。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Okazaki, T. et al.: "PD-1 immunoreceptor inhibits B cell receptor mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine"Proc. Natl. Acad. Sci. USA. 98. 13866-13871 (2001)
Okazaki, T. 等人:“PD-1 免疫受体通过将包含 src 同源 2 结构域的酪氨酸磷酸酶 2 募集到磷酸酪氨酸来抑制 B 细胞受体介导的信号传导”Proc.
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Nishimura H., et al.: "Facilitation of β selection and modification of positive selection in the thymus of PD-1 deficient mice"J.Exp.Med.. 191. 891-897 (2000)
Nishimura H.等人:“PD-1缺陷小鼠胸腺中β选择的促进和正选择的修饰”J.Exp.Med.. 191. 891-897 (2000)
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 14 条
Mechanism for genome instability by activation induced cytidine deaminase induced-reduction of topoisomerase1
-
批准号:22000015
-
项目类别:Grant-in-Aid for Specially Promoted Research
-
资助金额:$285.54万
-
财政年份:2010
-
负责人:HONJO Tasuku
-
依托单位:
AID-dependent genetic alteration mechanism to generate antigen-specific antibodies
-
批准号:17002015
-
项目类别:Grant-in-Aid for Specially Promoted Research
-
资助金额:$489.22万
-
财政年份:2005
-
负责人:HONJO Tasuku
-
依托单位:
Regulation of lymphocyte development by Notch/RBP-J signaling
-
批准号:16209018
-
项目类别:Grant-in-Aid for Scientific Research (A)
-
资助金额:$21.96万
-
财政年份:2004
-
负责人:HONJO Tasuku
-
依托单位:
Molecular analysis of TSK mouseas a model of scleroderma
-
批准号:10044275
-
项目类别:Grant-in-Aid for Scientific Research (B).
-
资助金额:$4.54万
-
财政年份:1998
-
负责人:HONJO Tasuku
-
依托单位:
Molecular Mechanism for the Class Switch Recombination of immunoglobulin Gene
-
批准号:07407004
-
项目类别:Grant-in-Aid for Scientific Research (A)
-
资助金额:$27.58万
-
财政年份:1995
-
负责人:HONJO Tasuku
-
依托单位:
Mechanisn of lymphocyte differentiation, molecular mechanisms of gene rearrangement and clonal deletion by antigenes
-
批准号:04102007
-
项目类别:Grant-in-Aid for Specially Promoted Research
-
资助金额:$117.76万
-
财政年份:1992
-
负责人:HONJO Tasuku
-
依托单位:
Molecular mechanisms for immunoglobulin class switching
-
批准号:02044082
-
项目类别:Grant-in-Aid for international Scientific Research
-
资助金额:$2.43万
-
财政年份:1990
-
负责人:HONJO Tasuku
-
依托单位:
国内基金
海外基金
登录
查看更多内容
基于PD-L1/PD-1通路探讨标本配穴电针调控Th17/Treg平衡改善肥胖胰岛素抵抗的作用机制
-
批准号:JCZRLH202600504
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
基于PD-1/PD-L1调控PI3K/AKT与MAPK/ERK通路探讨栀子苷-大黄素配伍改善脓毒症免疫抑制的作用
-
批准号:2026JJ81015
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:谢伶俐
-
依托单位:
具核梭杆菌通过PD-1/PD-L1通路调控牙周炎免疫微环境的机制与干预研究
-
批准号:2026JJ81697
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:赵丹唯
-
依托单位:
基于多模态影像组学的PD-1/PD-L1抑制剂敏感性乳腺癌患者智能筛选与疗效预测研究
-
批准号:2026JJ82702
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:蒋忠军
-
依托单位:
基于PD-1/PD-L1免疫调控的鄂产苍术抗肿瘤活性物质基础及其作用机制研究
-
批准号:JCZRLH202600076
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
基于生物学引导MRI-Transformer模型评估三阴性乳腺癌抗PD-1/PD-L1免疫治疗反应的研究
-
批准号:QN25H180017
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:洪敏萍
-
依托单位:
探索Reptin对PD-1/PD-L1通路在肝癌免疫微环境中的调控作用机制
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:苏晓茹
-
依托单位:
酪氨酸蛋白激酶Mer受体介导胃癌抗PD-1/PD-L1治疗耐药的作用机制研究
-
批准号:JCZRLH202500772
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
GPR183在PD-1/PD-L1阻断剂治疗NSCLC过程中调控T细胞应答的机制
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:侯令婕
-
依托单位:
TLR3介导的PD-1/PD-L1信号途径在流感病毒相关性心肌损伤中的作用
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:欧会林
-
依托单位: